Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074928 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,414
- Enrollment target
NCT04074928 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 2,414 participants.
The verdict
NCT04074928, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,414 participants
- Enrollment target
Study Summary
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age. The purpose of this study is to demonstrate that vaccination with QIVc elicits an immune response that is noninferior to that of a US-licensed comparator QIV containing the same virus strains, in children 6 months through 47 months of age.
Interventions
- BIOLOGICAL Comparator QIV
- BIOLOGICAL QIVc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,414 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2020-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074928
The ClinicalTrials.gov registry entry for NCT04074928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Comparator QIV is the first listed.
NCT04074928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04074928 about?
NCT04074928 is a clinical study titled "Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects". This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age. The purpose of this study is to demonstrate that vaccination with QIVc elicits an immune response that is n...
What is the current status of trial NCT04074928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,414 participants. The study started on 2019-09-06. Estimated completion is 2020-09-03.
What interventions are being tested in trial NCT04074928?
The interventions under investigation include: Comparator QIV (BIOLOGICAL), QIVc (BIOLOGICAL).
Who is sponsoring clinical trial NCT04074928?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.